SAN DIEGO, CA–(EMWNews – July 31, 2008) – BioBlocks, Inc., leading provider of chemical

building blocks and drug discovery chemistry outsourcing, today announced a

significant expansion of its international management team, which is

focused on capital efficient, results-driven chemistry for lead

optimization. The US team, which is closely tied to the latest drug

discovery research and technology, will continue to interface closely with

a highly trained team of scientists based in Hungary. To ensure seamless

integration and continued focus on strong, goal-oriented project

management, BioBlocks has added Warren Wade, Ph.D., Director of Medicinal

Chemistry, BioBlocks USA, and Katalin Gero, M.A., General Manager of

BioBlocks Hungary. These new additions will work closely with Peter Pallai,

Ph.D., CEO of BioBlocks USA, and Laszlo Urogdi, Ph.D., Director of

Medicinal Chemistry, BioBlocks Hungary. Together, they form a team that is

well positioned to meet the needs of pharmaceutical companies who are

turning increasingly to contract research organizations (CRO) to minimize

overhead and cut costs. By focusing on meeting drug discovery program

metrics, and utilizing an integrated international team, BioBlocks

represents a new generation of drug discovery CROs which will augment

pharmaceutical pipelines with intelligent and cost effective manpower.

Warren Wade, Ph.D., Director of Medicinal Chemistry, BioBlocks USA, has

experience advancing two small molecule candidates for Investigational New

Drug (IND) filings while a Director of Medicinal Chemistry at Neurocrine

Biosciences, Inc. The leading candidate is currently in Phase 2 trials for

endocrine indications. He was also involved in the discovery of other

preclinical compounds for obesity, acute and neuropathic pain, multiple

sclerosis, and insomnia indications. In this role, Dr. Wade managed

interdisciplinary drug discovery teams, timelines, and project goals.

During his time at Neurocrine he worked on lead discovery and optimization

for multiple classes of targets including GPCRs, ion channels and molecular

transporters. Prior to this, Dr. Wade was a Research Investigator at Abbott

where he was involved in developing their combinatorial chemistry program

to maturity, worked with the Abbott Fragment Based Lead Discovery group,

and gained experience with parallel synthesis. Dr. Wade brings his

first-hand experience in the application of new technologies for lead

optimization and his goal-oriented program management skills to BioBlocks’

international team. Working with Dr. Laszlo Urogdi at BioBlocks Hungary,

the two will effectively guide BioBlocks’ lead optimization collaborations

with a strong emphasis on medicinal chemistry.

Katalin Gero, in her new role as General Manager of BioBlocks Hungary, will

oversee its daily operations, forge a seamless transition during a time of

aggressive growth, and coordinate communication with BioBlocks USA. Her

significant management, logistics, and business experience is vital to

implementing project plans that meet pharmaceutical client needs. Formerly,

as the Director of Commerce at Izinta Trading Co., Ms. Gero launched

oncology and brachytherapy (sealed source radiotherapy) medical devices and

software onto the Hungarian market. In addition, she had P&L

responsibilities and effectively liaised internal and external groups

towards mutually beneficial objectives. She was previously at ICN Hungary

where she managed bulk exports and improved sales of their morphine

products worldwide. Ms. Gero’s extensive expertise interfacing

international pharmaceutical business with the management of talented

scientific teams is a strong complement to the BioBlocks international

team.

Peter Pallai, Ph.D., CEO and founder of BioBlocks, and a medicinal chemist

with 23 years of drug discovery experience, commented, “The addition of Dr.

Wade and Ms. Gero to our international team confirms BioBlocks’ commitment

to providing the most advanced and efficient drug discovery services to our

clients. Our results-based, hit to lead chemistry technologies and

expertise cover a broad range of therapeutic areas, and we look forward to

working with companies who are looking to leverage capital efficient

resources to strengthen their drug discovery portfolios.”

About BioBlocks

BioBlocks, Inc. was founded in San Diego, CA, in 2002 to provide chemistry

services and specialty building blocks to the drug discovery community.

Over the past six years, the company has been transformed into a leading

provider of medicinal chemistry services. BioBlocks also offers more than

1500 chemistry building blocks for drug discovery, including quinolines,

benzylpiperidines, and Beta-amino acids.

Contact: Dr. Peter Pallai CEO BioBlocks phone: (858) 558-5900